Lung cancer is the most common cause of cancer death in the United States. Importantly, little progress has been made over the past three decades in its treatment success, highlighting the need for additional therapeutic targets. Receptor tyrosine kinases are frequently implicated in the progression of lung cancer, and some tyrosine kinase inhibitors are effective clinically. However, these inhibitors are frequently met with drug resistance and subsequent relapse, suggesting the importance of investigations into these mechanisms and alternative targets. The Eph RTK family, especially EphB4, has recently emerged as important players in cancer biology. Here, EphB4 is demonstrated to be overexpressed and mutated in lung cancer and to undergo copy number gains. Furthermore, inhibition of EphB4 reduces growth of lung cancer in vitro and in vivo, while expression of wild-type and mutant EphB4 promotes cell growth. Finally, investigation into EphB4 signaling reveals broad involvement in tyrosine kinase activity. Overall, this work represents the first systematic investigation of the role of EphB4 in lung cancer and identifies it as a novel therapeutic target.
|Commitee:||Ahsan, Habibul, Cohen, Kenneth S., Lang, Deborah, Onel, Kenan|
|School:||The University of Chicago|
|School Location:||United States -- Illinois|
|Source:||DAI-B 72/12, Dissertation Abstracts International|
|Subjects:||Molecular biology, Oncology|
|Keywords:||Ephb4, Ephrin receptor, Lung cancer, Receptor tyrosine kinase|
Copyright in each Dissertation and Thesis is retained by the author. All Rights Reserved
The supplemental file or files you are about to download were provided to ProQuest by the author as part of a
dissertation or thesis. The supplemental files are provided "AS IS" without warranty. ProQuest is not responsible for the
content, format or impact on the supplemental file(s) on our system. in some cases, the file type may be unknown or
may be a .exe file. We recommend caution as you open such files.
Copyright of the original materials contained in the supplemental file is retained by the author and your access to the
supplemental files is subject to the ProQuest Terms and Conditions of use.
Depending on the size of the file(s) you are downloading, the system may take some time to download them. Please be